SCHEMBL2385191

SCHEMBL2385191

CSc1cccc(NC(=O)N2CCN(c3nsnc3OCc3ccnc(N)n3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
PI4KB Q9UBF8 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LIMK2 P53671 3/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PDGFRB P09619 1/20 0.39
TRPV1 Q8NER1 2/20 0.38
TP53 P04637 1/20 0.38
HCRTR1 O43613 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
P2RY12 Q9H244 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384177 0.89 NPC1 (0.46) MAPTPI4KBMEN1KMT2ALIMK2
SCHEMBL2384924 0.88 PI4KB (0.44) MAPTPI4KBMEN1KMT2ALIMK2
SCHEMBL2385777 0.88 LIMK2 (0.53) MAPTPI4KBMEN1KMT2ALIMK2
SCHEMBL2384728 0.88 TRPV1 (0.51) MAPTPI4KBMEN1KMT2ANPC1
SCHEMBL2384916 0.87 PI4KB (0.51) MAPTPI4KBMEN1KMT2APDGFRB
SCHEMBL2383841 0.87 PI4KB (0.43) PI4KBMEN1KMT2ALIMK2PDGFRB
SCHEMBL2382924 0.86 TRPV1 (0.53) MAPTMEN1KMT2ATRPV1MAPK1
SCHEMBL2384914 0.85 P2RY12 (0.46) MAPTPI4KBMEN1KMT2APDGFRB
SCHEMBL2381557 0.85 MAPT (0.41) MAPTPI4KBMEN1KMT2APDGFRB
SCHEMBL2384849 0.84 PI4KB (0.46) MAPTPI4KBLIMK2TRPV1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR MAPT 2716/4885PI4KB 213/4885MEN1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.